ARASENSnmCRPCmHSPCARAMISmetastatic hormone-sensitive prostate cancernon-metastatic castration-resistant prostate cancerDarolutamide
…AMIS) and metastatic hormone-sensitive prostate cancer (mHSPC) (ARASENS). Darolutamide was commercialised in 2020.Aim and Objectives To…